

Special Issue

Precision Medicine in Breast Cancer: From Epidemiology to Cancer Prevention, Screening and Early Detection

Message from the Guest Editor

A large body of literature heralds the potential benefits of precision medicine—a paradigm that uses individual variation in genes, environment, and lifestyle to improve disease prevention, diagnosis, and treatment. Breast cancer has been at the forefront of precision medicine. However, precision medicine approaches to breast cancer prevention have lagged behind advances in treatment. Expanding our ability to tailor and implement effective preventive interventions is necessary to fully realize the promise of precision medicine for public health. This Special Issue aims to showcase epidemiological, clinical, and translational research that moves the field toward the precision prevention of breast cancer. Research areas may include (but are not limited to) the following: improved risk assessment tools, novel biomarkers of risk, chemoprevention, genetic susceptibility, impact of precision medicine on health disparities, relevant data integration and analytic methods, and the implementation of precision prevention strategies.

Guest Editor

Dr. Anne Marie McCarthy

Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/124255

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)